Chromogenic in situ hybridisation (CISH) should be an accepted method in the routine diagnostic evaluation of HER2 status in breast cancer
AUTOR(ES)
Di Palma, S
FONTE
BMJ Group
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1972421Documentos Relacionados
- Chromogenic in situ hybridization (CISH): a novel alternative in screening archival breast cancer tissue samples for HER-2/neu status
- HER2 status in breast cancer—an example of pharmacogenetic testing
- HER2 evaluation using the novel rabbit monoclonal antibody SP3 and CISH in tissue microarrays of invasive breast carcinomas
- MYC amplification in breast cancer: a chromogenic in situ hybridisation study
- Chromogenic in situ hybridization compared with other approaches to evaluate HER2/neu status in breast carcinomas